Assembling the human immunodeficiency virus type 1

Cellular and Molecular Life Sciences

Volumn 59, Issue 7, 2002, Pages 1166-1184

  Cimarelli, A ^a   Darlix, J L ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

Gag virion assembly; HIV 1; Raft; Retrovirus

Indexed keywords

STRUCTURAL PROTEIN;

BIOMEDICINE; CELL MEMBRANE; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; NONHUMAN; RETROVIRUS; REVIEW; VIRION; VIRUS ASSEMBLY;

CELL MEMBRANE; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, VIF; GENE PRODUCTS, VPU; GENES, VIRAL; HIV-1; MODELS, BIOLOGICAL; PROTEIN STRUCTURE, TERTIARY; RNA, VIRAL; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; RETROVIRIDAE; UNIDENTIFIED RETROVIRUS;

EID: 0036635446     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-002-8495-6     Document Type: Review

References (287)

1. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
2. Cellular latency in HIV-1 infection
3. Inhibitors of HIV-1 transcription
4. Chromatin control of HIV-1 gene expression
5. The role of chromatin in HIV-1 transcriptional regulation
6. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter
7. HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA
8. Tackling Tat
9. The ins and outs of HIV
10. The HIV-1 Rev protein
11. Intracellular transport of retroviral capsid components
12. HIV-1 gag proteins: Diverse functions in the virus life cycle
13. Assembly of type C oncornaviruses: A model
14. Quantitative electron microscopy of intracytoplasmic type A particles at kinetochores of metaphase chromosomes isolated from Chinese hamster and murine cell lines
15. An ultrastructural study of C-type virion assembly in mouse cells
16. Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids
17. Electron microscopy of mammalian type-C RNA viruses: Use of conditional lethal mutants in studies on virion maturation and assembly
18. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles
19. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells
20. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector
21. Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors
22. In vitro assembly of human immunodeficiency virus type 1 Gag protein
23. Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells
24. Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid
25. Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: Cis and trans effects on the Gag precursor assembly pathway
26. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1
27. Matrix protein of Akv murine leukemia virus: Genetic mapping of regions essential for particle formation
28. Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal
29. Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly
30. Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids
31. Form, function and use of retroviral Gag proteins
32. Fatty acylation of proteins: New insights into membrane targeting of myristoylated and palmitoylated proteins
33. N myristylation of the human immunodeficiency virus type 1 gag polyprotein precursor in Saccharomyces cerevisiae
34. Chemical characterization of p17gag from human immunodeficiency virus as an N-terminally myristoylated protein
35. Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein
36. The membrane-binding domain of the Rous sarcoma virus Gag protein
37. Electrostatic interaction of myristoylated proteins with membranes: Simple physics, complicated biology
38. Electrostatics and the membrane association of Src: Theory and experiment
39. Amino-terminal basic residues of Src mediate membrane binding through electrostatic interation with acidic phospholipids
40. Crystal structures of the trimeric human immunodeficiency virus type I matrix protein: Implications for membrane association and assembly
41. Comparison of the NMR and X-ray structures of the HIV-1 matrix protein: Evidence for conformational changes during viral assembly
42. Membrane lipid microdomains and the role of PKCtheta in T cell activation
43. Floating the raft hypothesis: The roles of lipid rafts in B cell antigen receptor function
44. Floating the raft hypothesis: Lipid rafts play a role in immune cell activation
45. New views of BCR structure and organization
46. Co-stimulation and counter-stimulation: Lipid raft clustering controls TCR signaling and functional outcomes
47. Lipid rafts and signal transduction
48. The amplification of TCR signaling by dynamic membrane microdomains
49. Influenza virus assembly: Effect of influenza virus glycoproteins on the membrane association of M1 protein
50. Assembly of Sendal virus: M protein interacts with F and HN proteins and with the cytoplasmic tail and transmembrane domain of F protein
51. Transport of viral proteins to the apical membranes and interaction of matrix protein with glycoproteins in the assembly of influenza viruses
52. Measles virus structural components are enriched into lipid raft microdomains: A potential cellular location for virus assembly
53. Measles virus assembly within membrane rafts
54. Lipid rafts and pseudotyping
55. The Nef protein of HIV-1 associates with rafts and primes T cells for activation
56. Nef increases infectivity of HIV via lipid rafts
57. Lipid composition and fluidity of the human immunodeficiency virus
58. Budding of Rous sarcoma virus and vesicular stomatitis virus from localized lipid regions in the plasma membrane of chicken embryo fibroblasts
59. Phospholipid composition of Rous sarcoma virus, host cell membranes and other enveloped RNA viruses
60. Characterization of human immunodeficiency virus type 1 Vif particle incorporation
61. Cellular proteins in HIV virions
62. Efficient incorporation of HLA class II onto human immunodeficiency virus type 1 requires envelope glycoprotein packaging
63. Kinetic analysis of human immunodeficiency virus type 1 assembly reveals the presence of sequential intermediates
64. Multimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomains
65. Plasma membrane rafts play a critical role in HIV-1 assembly and release
66. Differential membrane binding of the human immunodeficiency virus type 1 matrix protein
67. Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding
68. Characterization of human immunodeficiency virus type 1 Pr55gag membrane association in a cell-free system: Requirement for a C-terminal domain
69. Segregation of leading-edge and uropod components into specific lipid rafts during T cell polarization
70. Compartmentalization of Ras proteins
71. A block to human immunodeficiency virus type 1 assembly in murine cells
72. Efficient assembly of an HIV-1/MLV Gag-chimeric virus in murine cells
73. Chimeric human immunodeficiency virus type 1 containing murine leukemia virus matrix assembles in murine cells
74. Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly
75. Modulation of HIV-like particle assembly in vitro by inositol phosphates
76. In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain
77. In vitro assembly of virus-like particles with Rous sarcoma virus Gag delition mutants: Identification of the p10 domain as a morphological determinant in the formation of spherical particles
78. Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria
79. A multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free system
80. Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro
81. Characterization of Rous sarcoma virus Gag particles assembled in vitro
82. Functional role of human immunodeficiency virus type 1 vpu
83. Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein
84. Specificity and sequence requirements for interactions between various retroviral Gag proteins
85. Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins
86. Molecular modelling study of HIV p17 gag (MA) protein shell utilising data from electron microscopy and X-ray crystallography
87. Detection of a trimeric human immunodeficiency virus type 1 Gag intermediate is dependent on sequences in the matrix protein, p17
88. Crystal structure of SIV matrix antigen and implications for virus assembly
89. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain
90. The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly
91. Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production
92. Organization of HIV-1 capsid proteins on a lipid monolayer
93. Self-assembly in vitro of purified CA-NC proteins from Rous sarvoma virus and human immunodeficiency virus type 1
94. Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro
95. HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: Structure switching by pH-induced conformational changes
96. Assembly and analysis of conical models for the HIV-1 core
97. A conformational switch controlling HIV-1 morphogenesis
98. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly
99. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein
100. Structure of the amino-terminal core domain of the HIV-1 capsid protein
101. Crystal structure of dimeric HIV-1 capsid protein
102. Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab
103. Image reconstructions of helical assemblies of the HIV-1 CA protein
104. Functional domains of the capsid protein of human immunodeficiency virus type 1
105. Role of the major homolgy region of human immunodeficiency virus type 1 in virion morphogenesis
106. Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: Effects on virion particle assembly, release, and infectivity
107. Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation
108. Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation
109. Sequence requirements for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles
110. Human immunodeficiency virus type 1 virion density is not determined by nucleocapsid basic residues
111. The role of nucleocapsid of HIV-1 in virus assembly
112. Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation
113. Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA
114. Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein
115. Morphopoietic determinants of HIV-1 Gag particles assembled in baculovirus-infected cells
116. The central globular domain of the nucleocapsid protein of human immunodeficiency virus type 1 is critical for virion structure and infectivity
117. Role of the N-terminal zinc finger of human immunodeficiency virus type 1 nucleocapsid protein in virus structure and replication
118. Analysis of the assembly function of the human immunodeficiency virus type 1 gag protein nucleocapsid domain
119. The two zinc fingers in the human immunodeficiency virus type 1 nucleocapsid protein are not functionally equivalent
120. Identification of a binding site for the human immunodeficiency virus type 1 nucleocapsid protein
121. Rescue of multiple viral functions by a second-site suppressor of a human immunodeficiency virus type 1 nucleocapsid mutation
122. Possible roles of HIV-1 nucleocapsid protein in the specificity of proviral DNA synthesis and in its variability
123. 2+-dependent DNA integration in vitro
124. Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: Stimulation by the viral nucleocapsid protein
125. RNA packaging
126. First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses
127. NMR structure of the HIV-1 nucleocapsid protein bound to stem-loop SL2 of the psi-RNA packaging signal: Implications for genome recognition
128. Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element
129. 1H NMR structure and biological studies of the His23→Cys mutant nucleocapsid protein of HIV-1 indicate that the conformation of the first zinc finger is critical for virus infectivity
130. Structural analysis of human immunodeficiency virus type 1 Gag protein interactions, using cysteine-specific reagents
131. Spatial proximity of the HIV-1 nucleocapsid protein zinc fingers investigated by time-resolved fluorescence and fluorescence resonance energy transfer
132. 1H NMR
133. 1H NMR
134. Influence of the N- and C-terminal chains on the zinc-binding and conformational properties of the central zinc-finger structure of Moloney murine leukaemia virus nucleocapsid protein: A steady-state and time-resolved fluorescence study
135. Capsid assembly and DNA packaging in herpes simplex virus
136. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles
137. Self-assembly of purified polyomavirus capsid protein VP1
138. A theoretical model successfully identifies features of hepatitis B virus capsid assembly
139. The initiation of papaya mosaic virus assembly
140. The self-assembly of spherical plant viruses
141. Structure and assembly of turnip crinkle virus. II. Mechanism of reassembly in vitro
142. In vitro assembly of alphavirus cores by using nucleocapsid protein expressed in Escherichia coli
143. The core protein of the alphavirus Sindbis virus assembles into core-like nucleoproteins with the viral genome RNA and with other single-stranded nucleic acids in vitro
144. Formation of stable and functional HIV-1 nucleoprotein complexes in vitro
145. Refined solution structure of the dimeric N-terminal HHCC domain of HIV-2 integrase
146. HIV integrase structure and function
147. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
148. Solution structure of the DNA binding domain of HIV-1 integrase
149. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
150. Expression, purification, and crystallization of the HIV-1 reverse transcriptase (RT)
151. 2.2 A resolution structure of the amino-terminal half of HIV-1 reverse transcriptase (fingers and palm subdomains)
152. Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease
153. In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus
154. Mutations of basic amino acids of NCp7 of human immunodeficiency virus type 1 affect RNA binding in vitro
155. Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation
156. RNA is a structural element in retrovirus particles
157. A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology
158. Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1
159. Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line
160. Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA
161. The major HIV-1 packaging signal is an extended bulged stem loop whose structure is altered on interaction with the Gag polyprotein
162. Formation of virus assembly intermediate complexes in the cytoplasm by wild-type and assembly-defective mutant human immunodeficiency virus type 1 and their association with membranes
163. Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells
164. Tsg101 and the vacuolar protein sorting pathway are exxentiaI for HIV-1 budding
165. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release
166. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease
167. Ubiquitin is part of the retrovirus budding machinery
168. Mutations altering the Moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle
169. Ubiquitin in retrovirus assembly: Actor or bystander?
170. Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins
171. Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly
172. Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells
173. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag)
174. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress
175. Sorting in the endosomal system in yeast and animal cells
176. Ubiquitin in avian leukosis virus particles
177. Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus
178. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2
179. A role for ubiquitin ligase recruitment in retrovirus release
180. Ubiquitination of HIV-1 and MuLV Gag
181. A new ticket for entry into budding vesicles-ubiquitin
182. Mapping of poly(A) sequences in the electron microscope reveals unusual structure of type C oncornavirus RNA molecules
183. Evidence for 30-40S RNA as precursor of the 60-70S RNA of Rous sarcoma virus
184. Evidence for 30-40S RNA as precursor of the 60-70S RNA of Rous sarcoma virus
185. The oncornavirus maturation process: Quantitative correlation between morphological changes and conversion of genomic virion RNA
186. Solution studies of the dimerization initiation site of HIV-1 genomic RNA
187. Dimer initiation sequence of HIV-1 Lai genomic RNA: NMR solution structure of the extended duplex
188. Kissing-loop model of HIV-1 genome dimerization: HIV-1 RNAs can assume alternative dimeric forms, and all sequences upstream or downstream of hairpin 248-271 are dispensable for dimer formation
189. Moloney murine sarcoma virus genomic RNAs dimerize via a two-step process: A concentration-dependent kissing-loop interaction is driven by initial contact between consecutive guanines
190. Dimerization of retroviral genomic RNAs: Structural and functional implications
191. Identification of the primary site of the human immunodeficiency virus type 1 RNA dimerization in vitro
192. Evidence for interstrand quadruplex formation in the dimerization of human immunodeficiency virus 1 genomic RNA
193. NMR analysis of intra- and inter-molecular stems in the dimerization initiation site of the HIV-1 genome
194. HIV-1 nucleocapsid protein induces 'maturation' of dimeric retroviral RNA in vitro
195. Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions
196. Nucleocapsid protein 10 activates dimerization of the RNA of Moloney murine leukaemia virus in vitro
197. Maturation of dimeric viral RNA of Moloney murine leukemia virus
198. Proteolytic processing of the p2/nucleocapsid cleavate site is critical for human immunodeficiency virus type 1 RNA dimer maturation
199. The kissing hairpin sequence promotes recombination within the HIV-I 5′ leader region
200. The multimerization state of retroviral RNA is modulated by ammonium ions and affects HIV-1 full-length cDNA synthesis in vitro
201. The recombination rate is not increased when retroviral RNA is missing an encapsidation sequence
202. Nucleocapsid protein of human immunodeficiency virus as a model protein with chaperoning functions and as a target for antiviral drugs
203. Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: Significance for viral replication
204. Comparison of viral genomic RNA sorting mechanisms in human immunodeficiency virus type 1 (HIV-1), HIV-2, and Moloney murine leukemia virus
205. The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site
206. Rous sarcoma virus translation revisited: Characterization of an internal ribosome entry segment in the 5′ leader of the genomic RNA
207. An internal ribosome entry segment promotes translation of the simian immunodeficiency virus genomic RNA
208. Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein
209. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions
210. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix
211. Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains
212. Characterization of human immunodeficiency virus type 1 matrix revertants: Effects on virus assembly, Gag processing, and Env incorporation into virions
213. The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions
214. Direct interaction between the envelope and matrix proteins of HIV-I
215. Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles
216. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail
217. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts
218. Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity
219. The intracytoplasmic domain of gp41 mediates polarized budding of human immunodeficiency virus type 1 in MDCK cells
220. Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells
221. The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated
222. Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins
223. Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein
224. Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family
225. Endocytosis of endogenously synthesized HIV-1 envelope protein: Mechanism and role in processing for association with class II MHC
226. The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adapter
227. Mutations in the matrix protein of human immunodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glycoproteins in CD4+ T lymphocytes
228. Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly
229. Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers
230. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles
231. Over-expression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity
232. Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation
233. Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage
234. Cleavage of p15 protein in vitro by human immunodeficiency virus type 1 protease is RNA dependent
235. Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease
236. Subcellular localization of the Vif protein of human immunodeficiency virus type 1
237. Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein
238. The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells
239. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures
240. Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag
241. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA
242. Role of Vif in stability of the human immunodeficiency virus type 1 core
243. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions
244. Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells
245. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins
246. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes
247. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles
248. Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity
249. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein
250. The replicative impairment of Vif- mutants of human immunodeficiency virus type 1 correlates with an overall defect in viral DNA synthesis
251. Evidence for a newly discovered cellular anti-HIV-1 phenotype
252. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1
253. Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps
254. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells
255. Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription
256. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription
257. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding an packaging process
258. Identification of a protein encoded by the vpu gene of HIV-1
259. Human immunodeficiency virus type 1 Vpu protein is an oligometric type I integral membrane protein
260. Functional analysis of the phosphorylation sites on the human immunodeficiency virus type 1 Vpu protein
261. Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4
262. Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells
263. Structural and functional analysis of the membrane-spanning domain of the human immunodeficiency virus type 1 Vpu protein
264. HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology
265. The downregulation of CD4 and MHC-I by primate lentiviruses: A paradigm for the modulation of cell surface receptors
266. Modulation of cell surface protein expression by infection with HIV-1
267. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses
268. Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome
269. Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes
270. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein
271. A novel gene of HIV-1, vpu, and its 16-kilodalton product
272. Cell type-dependence for Vpu function
273. Function of human immunodeficiency virus type 1 Vpu protein in various cell types
274. Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation
275. Effects of Vpu expression on Xenopus oocyte membrane conductance
276. The structure of the HIV-1 Vpu ion channel: Modelling and simultation studies
277. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels
278. The human immunodeficiency virus type 1 Vpu protein enhances membrane permeability
279. Ion channels formed by HIV-1 Vpu: A modelling and simulation study
280. Identification of an ion channel acitivity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells
281. Viral ion channels: Molecular modeling and simulation
282. Annexins in cell membrane dynamics: Ca(2+)-regulated association of lipid microdomains
283. + channels to distinct lipid raft populations: Targeting of Kv1.5 to caveolae
284. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses
285. Compatibility of Vpu-like activity in the four groups of primate immunodeficiency viruses